Q2 2024 Bioventus Inc Earnings Call Transcript
Key Points
- Bioventus Inc (BVS) achieved a 14% organic revenue growth in the second quarter, marking the third consecutive quarter of double-digit growth.
- The company reported its highest adjusted EBITDA to date at over $34 million, with a 224-basis point increase in adjusted EBITDA margin.
- The Surgical Solutions segment saw a 16% revenue increase, driven by strong performance in Ultrasonics and Bone Graft Substitutes.
- The Pain Treatments segment experienced a 17% revenue increase, supported by strong demand for Durolane and effective commercial execution.
- Bioventus Inc (BVS) improved its liquidity position by reducing its net leverage ratio and increasing cash flow, with expectations to reduce the ratio below 3x by the end of 2025.
- The Restorative Therapies segment experienced a 9% decline in sales, primarily due to the divestiture of the Wound Business.
- The company plans to divest its Advanced Rehabilitation business, which may impact its focus and resources on core businesses.
- Despite strong performance, the company anticipates a step down in adjusted EBITDA and margins in the second half of the year due to strategic investments.
- The International segment only grew by 4%, with growth expected to accelerate in the latter half of the year due to previous shipment delays.
- Operating expenses increased by nearly $10 million compared to the prior year, driven by higher sales commissions and increased headcount.
Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. (Operator Instructions). Please note this event is being recorded.
I would now like to turn the conference over to Dave Crawford, Vice President of Investor Relations. Please go ahead.
Thanks, Danielle, and good morning, everyone, and thanks for joining us. It is my pleasure to welcome you to the Bioventus 2024 Second Quarter Earnings Conference Call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO.
Rob will begin his remarks with an update on our 2024 priorities and our business, and Mark will provide detail of our second quarter results and discuss our updated 2024 financial guidance. We'll finish the call with Q&A. A presentation for today's call is available on the Investors section of our website, bioventus.com.
But before I begin, I would like to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
